Net sales and operating profit surged in Q2 and H1 2026, driven by Nubeqa royalties and Branded Products. Guidance was raised, with continued growth expected in Innovative Medicines and stable performance in other divisions. Tariffs and shipment timing pose minor risks.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.